Quoin Pharmaceuticals Ltd DRC
$ 6.49
3.02%
15 Apr - close price
- Market Cap 11,362,800 USD
- Current Price $ 6.49
- High / Low $ 6.60 / 6.26
- Stock P/E N/A
- Book Value 8.76
- EPS -518.00
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.56 %
- ROE -1.42 %
- 52 Week High 23.50
- 52 Week Low 5.27
About
Quoin Pharmaceuticals Ltd (QNRX) is a biotechnology company dedicated to developing innovative therapeutics targeting rare diseases and unmet medical needs. Leveraging advanced drug delivery technologies, Quoin aims to improve the efficacy and safety of existing compounds, thereby strengthening its foothold in the specialty pharmaceuticals landscape. The company's promising pipeline features therapies addressing critical health conditions, offering potential for significant clinical advancements and commercial opportunities. Committed to delivering value for patients and investors alike, Quoin actively pursues strategic collaborations and pioneering research initiatives.
Analyst Target Price
$29.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-31 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-11 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-08 | 2023-08-02 | 2023-05-08 |
| Reported EPS | -1.74 | -6.72 | -6.3 | -6.502 | -0.2781 | -0.47 | -0.39 | -1.11 | -2.08 | -1.95 | -2.13 | -0.34 |
| Estimated EPS | -4.02 | -0.6 | -0.56 | -4.2 | -0.43 | -0.49 | -0.61 | -0.76 | -2.31 | -2.72 | -2.82 | -0.28 |
| Surprise | 2.28 | -6.12 | -5.74 | -2.302 | 0.1519 | 0.02 | 0.22 | -0.35 | 0.23 | 0.77 | 0.69 | -0.06 |
| Surprise Percentage | 56.7164% | -1020% | -1025% | -54.8095% | 35.3256% | 4.0816% | 36.0656% | -46.0526% | 9.9567% | 28.3088% | 24.4681% | -21.4286% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QNRX
2026-04-01 14:11:18
This article analyzes the valuation of Quoin Pharmaceuticals Ltd (QNRX). It suggests that QNRX is currently in the "Fair zone" based on its forward PS ratio compared to its five-year average. The company's Price-to-Book ratio is significantly higher than its 3-year and 5-year averages, while its Forward Free Cash Flow yield is substantially lower.
2026-04-01 03:09:17
Stonepine Capital Management, LLC, a ten percent owner of Quoin Pharmaceuticals, Ltd. (QNRX), has filed a Form 4 with the SEC, indicating no reported purchases, sales, or other share transactions. The filing notes that due to a change in outstanding shares, Stonepine Capital now beneficially owns less than 10% of Quoin Pharmaceuticals' outstanding ordinary shares, despite being classified as a 10% owner on the form. This Form 4 suggests a neutral impact on sentiment as it reports no new trading activity.
2026-03-31 17:10:14
Quoin Pharmaceuticals (QNRX) faces significant financing risks due to restrictive covenants in its October 2025 Purchase Agreement, limiting its ability to secure variable rate and equity financings. These limitations, combined with the purchasers' participation rights, could lead to funding shortfalls and program delays. Analysts project a potential upside of 485.02% for QNRX stock, with an average target price of $37.50.
2026-03-29 01:04:00
Quoin Pharmaceuticals Ltd. (QNRX) faces significant financing risks due to covenants in its October 2025 Purchase Agreement, restricting variable rate financings until April 2026 and equity financings below a certain price until June 2026. These limitations, coupled with the purchasers' participation rights, could hinder the company's ability to secure timely funding. This may lead to program delays or terminations, adversely impacting its business and financial health.
2026-03-28 05:39:07
Quoin Pharmaceuticals Ltd (QNRX) faces significant financing risks due to restrictive covenants from its October 2025 Purchase Agreement, limiting variable rate and equity financings until specific dates in 2026. These limitations, coupled with a 25% participation right for October Purchasers, could hinder the company's ability to secure necessary funding. This situation potentially leads to program delays or terminations, adversely affecting Quoin's business and financial health, despite an average stock price target of $37.50, suggesting a 485.02% upside potential.
2026-03-27 16:09:40
Alliance Global has increased its price target for Quoin Pharmaceuticals (QNRX) to $35 from $25, while maintaining a Buy rating on the shares. This adjustment is primarily due to a higher valuation placed on priority review vouchers, based on the firm's sum-of-the-parts analysis. The Fly first reported this update, highlighting its significance for investors in Quoin Pharmaceuticals.
